Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables (2017 - 2025)

Dianthus Therapeutics has reported Change in Account Payables over the past 8 years, most recently at $3.0 million for Q3 2025.

  • Quarterly results put Change in Account Payables at $3.0 million for Q3 2025, down 46.84% from a year ago — trailing twelve months through Sep 2025 was $6.9 million (down 8.53% YoY), and the annual figure for FY2024 was $8.2 million, up 1139.18%.
  • Change in Account Payables for Q3 2025 was $3.0 million at Dianthus Therapeutics, down from $3.1 million in the prior quarter.
  • Over the last five years, Change in Account Payables for DNTH hit a ceiling of $5.7 million in Q3 2024 and a floor of -$4.7 million in Q1 2023.
  • Median Change in Account Payables over the past 4 years was $1.4 million (2022), compared with a mean of $842933.3.
  • Biggest five-year swings in Change in Account Payables: tumbled 438.27% in 2023 and later soared 631.05% in 2024.
  • Dianthus Therapeutics' Change in Account Payables stood at -$339000.0 in 2022, then soared by 572.86% to $1.6 million in 2023, then surged by 42.23% to $2.3 million in 2024, then surged by 31.75% to $3.0 million in 2025.
  • The last three reported values for Change in Account Payables were $3.0 million (Q3 2025), $3.1 million (Q2 2025), and -$1.5 million (Q1 2025) per Business Quant data.